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Chronic kidney diseases – arising from inborn or acquired renal disorders – are one of the
most common causes of secondary hypertension. Renal parenchymatous hypertension
accompanying bilateral or unilateral kidney diseases is more prevalent than renovascular
hypertension. The prevalence and severity of hypertension are inﬂuenced by age, weight,
type of renal afﬂiction, and depth of renal dysfunction. In multifactorial pathogenesis,
sodium retention plays the crucial role together with dysbalance concerning effects of
different vasoactive substances; however, unequivocal distinction between volume- and
renin-type hypertension is difﬁcult. The treatment of renal hypertension includes appro-
priate lifestyle changes, pharmacotherapy, hemoelimination methods and radiological or
urological invasive procedures. In chronic kidney diseases with increased albuminuria or
proteinuria, ACE inhibitors and AT1-blockers are preferred. Combination of several
antihypertensives is often required to achieve the target blood pressure. Increased blood
pressure represents not only the manifestation of chronic kidney diseases but also an
important factor concerning the renal and cardiovascular risk.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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The relationship between increased blood pressure (BP) and
kidneys is multidirectional. The kidneys participate in the
development and perpetuation of essential hypertension.
Chronic kidney diseases (CKDs) are one of the most common
causes of secondary hypertension. On the other hand, hyperten-
sion of any etiology can lead to renal impairment (benign or
malignant nephrosclerosis) and increased BP accompanied by
proteinuria is an important factor related to CKD progression.
According to the initial estimates, every 10th adult suf-
fered from CKD worldwide. However, the prevalence of CKD
in the US increased from 10% (1988–1994) to 13% (1999–2004)
of the adult population [1]. Similar data about the high CKD
rate were collected in other continents – in China (13%;[2])
and Australia (16%;[3]). Patients with diabetes mellitus, arter-
ial hypertension and cardiovascular (CV) diseases have
increased risk of CKD development. Early CKD stages often
remain unrecognized. The rising number of CKD patients
currently represents an important medical, economical and
social problem globally [4].
New international guidelines were published in the last
two years, dealing both with the renal hypertension and with
CKD [5,6].2. Deﬁnition and classiﬁcation of chronic
kidney diseases
CKD is deﬁned by the presence of at least one marker of renal
impairment for more than three months (pathological ﬁnd-
ings in urine and urine sediment, changes in serum concen-
trations of creatinine or electrolytes, histological or structural
abnormalities found by kidney biopsy or imaging) and/or
glomerular ﬁltration rate o1 ml/s/1.73 m2 [7,8] – see Table 1.
New CKD classiﬁcation was created after 10 years [6], reﬂect-
ing the cause of the disease, estimate of glomerular ﬁltration
rate but also quantiﬁcation of albuminuria. Instead of theTable 1 – Original CKD classiﬁcation (adapted from [7,8])
CKD stage
(1) Renal impairment with normal or increased GFR
(2) Renal impairment with mild GFR decrease
(3) Mild chronic renal insufﬁciency
(4) Severe chronic renal insufﬁciency
(5) Chronic renal failure
GFR – glomerular ﬁltration rateoriginal ﬁve, it includes six stages of severity – see Tables 2
and 3. The original stage 3 CKD is now divided into 3a and 3b
to allow for better risk stratiﬁcation.3. Hypertension in chronic kidney diseases
The prevalence of renal hypertension is 5–6% [9]. Increased
blood pressure accompanies both inborn and acquired, bilat-
eral or unilateral CKDs [10]. The presence and severity of
hypertension are inﬂuenced by age, weight, type and dura-
tion of renal afﬂiction, and depth of renal dysfunction. Renal
hypertension is responsible for 60–80% cases of secondary
hypertension in children and adolescents [11]. Hypertension
is present in 80–85% adult patients with CKD [12]. While the
prevalence of hypertension in people without renal dysfunc-
tion is 60%, it can be as high as 90% in patients with chronic
renal failure.4. Pathogenesis of hypertension in chronic
kidney diseases
Bilateral CKD is characterized by sodium and water retention,
leading to increases of plasma volume and cardiac output. The
hypertension is perpetuated by dysbalance in the effects of
various vasoactive substances [13,14] – activation/insufﬁcient
suppression of vasoconstriction systems (renin–angiotensin–
aldosterone, sympathetic system) and decreased production of
vasodilatory agents (NO, prostaglandins). Secondary hyperpar-
athyroidism, accompanied by increase of the intracellular
calcium concentration, can lead to vasoconstriction and hyper-
tension. In unilateral CKDs, activation of the renin-angiotensin
system plays an important role. Most often, it is caused by
ischemia, which can be related to scar formation in inﬂamma-
tory diseases, pressure of masses (tumors, solitary cysts) or
calyx dilation in hydronephrosis. Unequivocal distinction
between volume- and renin-type hypertension is difﬁcult sinceGFR (ml/s/1.73 m2) GFR (ml/min/1.73 m2)
≥1.5 ≥90
1.00–1.49 60–89
0.50–0.99 30–59
0.25–0.49 15–29
o0.25 or dialysis o15 or dialysis
Table 2 – New CKD classiﬁcation [6]
CKD stage GFR (ml/s/1.73 m2) GFR (ml/min/1.73 m2)
(1) Normal or high GFR ≥1.5 ≥90
(2) Mildly decreased GFR 1.00–1.49 60–89
(3a) Mildly to moderately decreased GFR 0.75–0.99 45–59
(3b) Moderately to severely decreased GFR 0.50–0.74 30–44
(4) Severely decreased GFR 0.25–0.49 15–29
(5) Renal failure o0.25 or dialysis o15 or dialysis
Table 3 – Categories of albuminuria in CKD (adapted from [6])
Category AU (mg/24 h) A/Cr (mg/mmol) A/Cr (mg/g)
A1 Normal to mildly elevated o30 o3 o30
A2 Moderately elevated 30–300 3–30 30–300
A3 Severely elevated 4300 430 4300
AU – albuminuria, A/Cr – urine albumin/creatinine ratio
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ﬁltration function of the kidney worsens, renal insufﬁciency
and renal failure develop and the contribution of sodium and
water retention to the perpetuation of high blood pressure
increases substantially. Hypertension (or loosening of its con-
trol) can also be worsened by the therapy of renal anemia with
recombinant human erythropoietin. In systolic hypertension,
major role is played by calciﬁcations, decreased elasticity of
large arteries, and also by the common presence of hyperki-
netic circulation caused by anemia and arteriovenous anasto-
mosis created to make hemodialysis possible.5. Chronic kidney diseases and hypertension
Primary afﬂictions of renal tissue causing parenchymatous
hypertension are more common that afﬂictions of renal arteries
leading to renovascular hypertension. In bilateral CKD, hyper-
tension is the most common in glomerular diseases; of non-
glomerular diseases, hypertension is the most prevalent in
autosomal dominant polycystic kidney disease. Hypertension
also accompanies numerous inborn and acquired, inﬂamma-
tory or oncologic unilateral kidney processes.5.1. Glomerulonephritides
Hypertension accompanies both primary and secondary glo-
merular diseases. Its prevalence in chronic glomerulonephri-
tides amounts to 30–90%. It affects up to 50% of patients with
the globally most prevalent primary glomerulonephritis – IgA
nephropathy (Berger's disease) and 70–80% of patients with
membranoproliferative glomerulonephritis or focal segmen-
tal glomerulosclerosis. The most common secondary glomer-
ulopathy is diabetic glomerulosclerosis, with hypertension
present since the stage of microalbuminuria and rising in
prevalence along with the development of manifest protei-
nuria (up to 80% of patients with type 2 diabetes).5.2. Autosomal dominant polycystic kidney disease
Hypertension develops in 50–70% of patients at the stage of
intact renal functions and in up to 100% of those with renal
insufﬁciency.5.3. Chronic tubulointerstitial nephritides
Hypertension is less common at early stage (affects about 30%
of patients) since the impairment of concentration capacity,
typical of renal medulla afﬂictions, leads to increased urinary
sodium losses and limits the increase of plasma volume. The
prevalence of hypertension rises along with further develop-
ment of the disease and with the decrease of kidney ﬁltration
function.5.4. Unilateral kidney disease
Hypertension is the most common in cases of unilateral
kidney shrinkage caused by chronic pyelonephritis and reﬂux
nephropathy. It can also accompany hydronephrosis, kidney
trauma, radiation nephritis, tuberculous infection or a large
solitary renal cyst. It is pronounced in 100% of cases of a rare
tumor arising from juxtaglomerular cells – hemangiopericy-
toma (reninoma), in 50% of children with nephroblastoma
(Wilms' tumor), and in 30% of adult patients with renal
carcinoma.5.5. Renovascular hypertension
Found in 1–2% of all hypertensive patients. The most com-
mon causes of hemodynamically signiﬁcant renal artery
stenosis are atherosclerosis (80%) and vascular ﬁbromuscular
dysplasia (20%).
Table 5 – Recommendation concerning pharmacotherapy
of adult patients with CKD – diabetics and non-diabetics
(adapted from [17])
Albuminuria
(mg/24 h)
Target blood
pressure (mmHg)
Preferred
antihypertensives
o30 ≤140/90 None
30–300 ≤130/80 ACE inhibitors/
AT1-blockers
4300 ≤130/80 ACE inhibitors/
AT1-blockers
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 9 7 – e 4 0 2e4006. Target blood pressure in chronic kidney
diseases
The aim of controlling hypertension in CKD is to decrease the
renal and CV risk. Not all CKD patients currently have the
same target BP [5] since the outdated nephrological state-
ment [15] that BP ≤130/80 mmHg is more beneﬁcial for CKD
patients with normal albuminuria than BP ≤140/90 mmHg is
no longer valid. The newly recommended target BP ≤140/≤90
mmHg is supported by a meta-analysis of 3 trials comprising
2272 patients [16]. Less robust evidence concerning subgroups
of these patients admits that lower target BP ≤130/≤80 mmHg
can be beneﬁcial for patients with albuminuria 430 mg/24 h.
The concept of individualized treatment with stratiﬁcation of
BP reﬂects not only the age and severity of albuminuria but
also the presence of CV comorbidities, e.g. heart failure. So
far, there is insufﬁcient evidence to recommend the stratiﬁ-
cation of target BP according to CKD stages [17]. Categories of
albuminuria and proteinuria are summarized in Table 4
(adapted from 5).7. Treatment of hypertension in chronic
kidney diseases – general rules
Non-pharmacologic (lifestyle changes) and combined phar-
macologic treatment are both necessary to achieve the target
BP. All types of antihypertensives are effective in CKD with
respect to lowering of the BP. When choosing the antihyper-
tensive medication, however, we prefer blockers of the renin-
angiotensin system because they prevent the development of
albuminuria. The therapy with ACE inhibitors or AT1-
blockers can be initiated at all stages of CKD with albumi-
nuria 430 mg/24 h, both in diabetics and non-diabetics
(Table 5). ACE inhibitors and AT1-blockers decrease the
systemic and glomerular pressure and they suppress albu-
minuria more effectively than other antihypertensives. ACE
inhibitors with dual elimination (fosinopril, spirapril and
trandolapril) are considered safer. The kidney: liver elimina-
tion ratio is especially favorable in trandolapril (33%: 66%), in
which dose adjustments are required only with glomerular
ﬁltration rate o30 ml/min.Table 4 – Categories of albuminuria and proteinuria
(adapted from [5])
Normal to
mildly
elevated
Moderately
elevated
Severely
elevated
AU (mg/24 h) o30 30–300 4300
PU (mg/24 h) o150 150–500 4500
A/Cr (mg/mmol) o3 3–30 430
A/Cr (mg/g) o30 30–300 4300
P/Cr (mg/mmol) o15 15–50 450
P/Cr (mg/g) o150 150–500 4500
AU – albuminuria, PU – proteinuria, A/Cr – urine albumin/creatinine
ratio, P/Cr – urine protein/creatinine ratio.8. Algorithm of antihypertensive treatment
in chronic kidney diseases with proteinuria
Antihypertensives of choice are ACE inhibitors or AT1-
blockers again. Combination therapy is often necessary, the
second- and third-choice antihypertensives being non-
dihydropyridine calcium channel blockers or diuretics. The
presence or absence of hyperhydration is decisive when
answering the question which should be used preferentially.
Diuretics combined with antihypertensives blocking the
renin–angiotensin system are preferred in CKD with manifest
edemas. Thiazide diuretics loose their effectiveness with GFR
o0.5 ml/s and are being replaced by loop diuretics (furose-
mide). When edemas persist, thiazides should be added to
the loop diuretics. The effect of chlorthalidone is stronger and
lasts longer than that of hydrochlorothiazide. Diuretics, as
well as salt intake restriction, potentiate both the antihyper-
tensive and anti-proteinuric effects of ACE inhibitors and
AT1-blockers. The dose of the diuretic has to be titrated
slowly in order to prevent possible hypotension. When no
hyperhydration is present, we prefer non-dihydropyridine
calcium channel blockers – especially verapamil, in which
anti-proteinuric effect was demonstrated [18]. A combination
of ACE inhibitors with AT1-blockers can be used in diabetic
and non-diabetic patients with CKD in the persistence of
proteinuria41 g/24 h despite achieving target blood pressure
by high doses of ACE inhibitors or AT1-blockers. Necessity is
a careful monitoring of possible side effects (decrease in GFR,
hyperkalemia).9. Algorithm of antihypertensive treatment
in chronic kidney diseases without proteinuria
When edemas are present, the antihypertensives of choice
are diuretics, second-choice antihypertensives being the ACE
inhibitors/AT1-blockers or dihydropyridine calcium channel
blockers. In the absence of edemas, therapy with ACE inhi-
bitors or AT1-blockers can be initiated; dihydropyridine
calcium channel blockers and diuretics can be added later on.
In cases of CKD with resistant hypertension (i.e. in cases
where the target BP was not reached using three antihyper-
tensives of different types at maximal recommended doses,
including a diuretic), the aldosterone antagonist spironolac-
tone – manifesting an anti-proteinuric effect beside
the antihypertensive one – represents the fourth choice.
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agents, beta-blockers or peripheral alpha-blockers.
Patients with CKD often manifest the so called non-
dipping phenomenon, i.e. the absence of physiological BP
pressure drop by at least 10% during sleep compared to the BP
values during the day (wakefulness). This phenomenon can
be demonstrated using the 24-h ambulatory BP monitoring
and it can be reversed by taking at least one antihypertensive
in the evening instead of morning. The non-dipping phenom-
enon, as well as nocturnal hypertension, is accompanied by
increased CV risk.10. Therapy of hypertension in adult patients
with chronic kidney disease treated by dialysis
The successful therapy mainly depends on appropriate
hemoelimination treatment planning such that the redun-
dant extracellular ﬂuid is removed without episodes of
hypotension. When failing to meet the optimal target BP,
which is deﬁned individually with respect to age, comorbid-
ities and CV/neurological status, pharmacotherapy is neces-
sary. All antihypertensives other than diuretics (with the
exception of dialyzed patients with preserved residual diur-
esis) are effective. Calcium channel blockers, ACE inhibitors
or AT1-blockers are used the most often. In most cases, these
have to be combined with other types of antihypertensives
(beta- or alpha-blockers). Some antihypertensives (ACE inhi-
bitors and certain beta-blockers) are being eliminated by
dialysis, which means that the choice of an individual
antihypertensive agent and timing of its application have to
be adjusted to this fact [19]. Effective control of hypertension
with ACE inhibitors, AT1-blockers, beta-blockers or calcium
channel blockers lowers the risk of CV events and both
general and CV mortality [20]. The KDIGO conference dealing
with BP in dialyzed patients (CKD 5) came to the conclusion in
2009 that many unresolved questions remain within this
topic – correct BP measurement in hemodialyzed patients,
relationship between BP and CV risk or the knowledge of
interaction of factors inﬂuencing the systolic and diastolic
BP [21].11. Treatment of renovascular hypertension
Treatment of renovascular hypertension includes pharma-
cotherapy and revascularization. Long-term pharmacother-
apy is indicated in patients with unilateral stenosis and
preserved renal function or mild renal dysfunction and in
cases where revascularization was not successful or is not
feasible (because of high periprocedural risk or the absence of
the patient's consent). Combination of several antihyperten-
sives – ACE inhibitors or AT1-blockers, calcium channel
blockers, diuretics and centrally acting agents – is required.
Pharmacotherapy takes part in the control of hypertension
and slows the progression of structural changes within the
kidney but it does not remove hypoperfusion, which – if long-
standing – can eventually lead to renal atrophy. Nowadays,
insufﬁcient control of hypertension is only rarely a reason forintervention concerning the renal artery since effective anti-
hypertensives are available.
The aim of revascularization therapy (percutaneous trans-
luminal angioplasty with stent implantation), leading to effec-
tive BP control just in younger patients with ﬁbromuscular
dysplasia (and only rarely in atherosclerotic stenoses in older
patients), is to prevent renal injury. Current indications of this
treatment include: stenosis of renal artery supplying anatomi-
cally or functionally solitary kidney, severe pharmacotherapy-
resistant hypertension, repeated episodes of pulmonary edema
or renal insufﬁciency progressing despite good BP control [22].12. Progression of chronic kidney diseases
and options concerning its treatment
CKDs, especially those accompanied by albuminuria or pro-
teinuria, are of progressive nature. The ﬁltration function of
the kidney deteriorates by 2–8 ml/min every year, depending
on the etiology of renal impairment [23]. Progression of CKD
is associated with increased CV risk and has profound effects
on patients' morbidity and mortality.
Risk factors for progression of pre-existing CKD include
[24,25]: (a) Unchangeable factors – CKD type (diabetic nephro-
pathy, glomerulonephritides, polycystic kidneys), decreased
number of nephrons and presence of cardiovascular disease;
(b) Factors that can be changed with treatment – proteinuria,
hypertension, obesity, high protein intake, anemia, dyslipi-
demia, smoking, hyperuricemia and hypoproteinemia [26].
The rate and severity of progression are classiﬁed with
respect to the serum creatinine level, quantiﬁcation of glo-
merular ﬁltration rate decline and reaching of end-stage renal
disease requiring dialysis or transplantation.
Early CKD diagnosis including its etiology makes it possible –
especially in cases with glomerular involvement – to initiate
speciﬁc therapy that aims at stopping or (ideally) reversing the
progression of CKD. In CKD diagnosed at later stages where
substantial number of nephrons have vanished and no clear
effect of speciﬁc therapy can be expected, the progression can be
halted by effective BP control and by diminishing albuminuria/
proteinuria using pharmacologic blockade of the renin–angio-
tensin–aldosterone system.
Prevention of CKD progression in patients suffering from
type 2 diabetes mellitus can be divided into:(1) Primary: In the BENEDICT trial, ACE inhibitor trandolapril
diminished the risk of microalbuminuria by 53% in nor-
moalbuminuric patients compared with placebo; when
combined with non-dihydropyridine calcium channel
blocker, it lowered this risk even further by 61% [27]. This
favorable outcome is explained by interaction between
trandolapril and vas efferens and by proportional effect of
non-dihydropyridine calcium channel blocker on both
glomerular vas efferens and afferens when the given
combination is used;(2) Secondary: In the IRMA 2 trial, AT1-blocker irbesartan
reduced the rate of progression from microalbuminuria to
manifest proteinuria by 70% compared with placebo [28];(3) Tertiary: Compared with placebo, AT1-blockers losartan
(the RENAAL trial) and irbesartan (the IDNT trial) slowed
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 9 7 – e 4 0 2e402the progression of chronic renal insufﬁciency by 18% and
20%, respectively [29,30].
13. Conclusion
CKDs represent a major cause of secondary hypertension.
New international guidelines stress the individual approach
to deﬁning of the target blood pressure with respect to age,
severity of albuminuria and presence of CV comorbidities.
The algorithm of antihypertensive treatment depends on the
presence or absence of proteinuria. Agents blocking the
renin-angiotensin system are being used both in diabetics
and non-diabetics suffering from CKD. Hypertension control
and treatment of other changeable risk factors form an
essential part of effective preventive measures slowing the
CKD progression.
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